Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: A case report

16Citations
Citations of this article
54Readers
Mendeley users who have this article in their library.

Abstract

As the newer oral anticoagulants (NOACs) are increasingly used in older patients, clinical scenarios when they may need to be discontinued temporarily or indefinitely, may be encountered. Similarly with increasing use of permanent pacemakers and other intra-cardiac devices, there is an increased risk of upper limb venous thrombosis even few years after their insertion. We report a case of a patient with a permanent pacemaker, on rivaroxaban (NOAC) for atrial fibrillation, who developed an upper extremity deep vein thrombosis after its temporary withdrawal following a traumatic acute subdural haematoma. Physicians should be aware of the possibility of rebound hypercoagulability and venous thrombosis soon after the withdrawal of NOACs.

Cite

CITATION STYLE

APA

Nagasayi, S., Varman, S., Ting, Y. Y., & Ang, W. (2017). Rivaroxaban withdrawal and rebound hypercoagulability leading to upper extremity deep vein thrombosis: A case report. Age and Ageing, 46(5), 870–871. https://doi.org/10.1093/ageing/afx073

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free